Hepatitis/MASH

Patients with chronic hepatitis B (CHB) who received the Hecolin hepatitis E virus (HEV) 3-dose regimen had a somewhat low incidence of local and systemic adverse events.

DC646 had a strong safety profile, targeted intestinal FXR, and disrupted FXR-co-activator interactions in metabolic dysfunction-associated steatohepatitis (MASH).

Untargeted lipidomics identified a glycerophospholipid and sphingolipid signature that differentiated severe alcohol-related hepatitis (sAH) from decompensated cirrhosis (DC).

A team of clinical and academic experts from the Association of Anaesthetists produced a consensus statement outlining the key components to minimizing the impact of harmful alcohol intake in the surgical population.

Patients with metabolic dysfunction-associated steatohepatitis (MASH) receiving 300 mg of vitamin E daily presented improved steatosis, lobular inflammation, and fibrosis stages.

Although tenofovir amibufenamide and tenofovir disoproxil fumarate (TDF) had similar effects, the former resulted in better renal safety and did not impact lipid levels.

The long-term durability of response will be evaluated in the B-Sure trial (NCT04954859), which will enroll patients with hepatitis B virus (HBV) from B-Together (NCT04676724).

Although larsucosterol did not show statistical significance, it showed clinically meaningful trends in 90-day mortality in patients with severe alcohol-associated hepatitis.

This surgery can be significant in reducing the long-term risk of adverse outcomes and decompensation in cirrhosis related to metabolic dysfunction-associated steatohepatitis (MASH).

Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).

The model also predicted prevalent cases of decompensated cirrhosis would more than triple, incident liver cancer cases would nearly double, and transplant almost quadruple.

The authors note that this may cause disruptions in the metabolic stability of lipid processing and storage, impacting the liver and accelerating damaging adaptative responses.

The study shows benefits when Hecolin (HEV 239; Xiamen Innovax Biotech Co Ltd) is administered in 2 doses, rather than the typical 3-dose regimen.

Despite the reductions in hepatitis B surface antigen (HBsAg), grade 3 and 4 adverse events were not uncommon.

Severe alcohol-associated hepatitis has limited effective pharmacological therapies, emphasizing the need for treatment options.

The treatments are currently undergoing evaluation in the SOLSTICE trial (NCT05461170).

Survodutide is a glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonist that activates the glucagon and GLP-1 receptors to better control metabolic function.

Positive trial results laid the groundwork for the designation.

A lack of widespread hepatitis B screenings compound with the issue of inaccurate test results, which can complicate treatment with intravenous immunoglobulin.

Study finds traces of “epigenetic scars” on the immune cells of patients who recovered from chronic hepatitis C infection.

Treatment often involves a complex daily routine of reconstitution and subcutaneous injection, along with strict storage requirements.

In the 2 mg bulevirtide (Gilead Sciences) group, 44% of individuals achieved HDV RNA that was undetectable compared with 70% in the 10 mg group.

Investigators found improvements over the placebo in metabolic dysfunction-associated steatohepatitis without worsening fibrosis across 3 dosing groups.

The test can be performed in settings that operate under the Clinical Laboratory Improvement Amendments waiver, including community pharmacies.

Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.

Study investigators hired undercover shoppers, and the results revealed more education is needed on the Syringe Service Program, which provides legal, clean over-the-counter (OTC) needles to whomever seeks them out.

The primary outcome was a 90-day incidence of mortality or liver transplant for individuals who received larsucosterol, compared to the placebo group.

Hepatitis Awareness Month is designed to raise awareness of viral hepatitis and promote testing and vaccination while decreasing the stigma against the virus.

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases

The new indication includes pediatric patients aged 6 years and older who weigh at least 25 kg and have compensated liver disease.